China to Dominate Polyethylene Capacity Additions in Asia Through 2027, Forecasts GlobalData

China is set to register the highest polyethylene capacity additions in Asia, contributing about 41% of the region’s capacity additions by 2027, says GlobalData, a leading data and analytics company.

GlobalData’s latest report, “Polyethylene Industry Installed Capacity and Capital Expenditure (CapEx) Forecast by Region and Countries including details of All Active Plants, Planned and Anunced Projects, 2023-2027,” reveals that China leads with the largest polyethylene capacity additions in Asia, by gaining a capacity of 10.14 million tonnes per annum (mtpa) from 31 planned and five announced projects.

Nivedita Roy, Oil and Gas Analyst at GlobalData, Comments: “Increased demand for polyethylene in the food and beverage industry is the primary factory for a rise in demand for polyethylene in China.”  

In China, the main capacity addition would be from five planned and announced projects, with a capacity of 0.5 mtpa each.

The projects include Exxon Mobil Corporation Huizhou Polyethylene Plant, Oriental Energy Maoming Polyethylene Plant 1, Oriental Energy Maoming Polyethylene Plant 2, Sinopec and Ineos JV Tianjin Polyethylene Plant 1 and Tangshan Xu Yang Petrochemical Tangshan Polyethylene Plant 1.

Ineos JV Tianjin Polyethylene Plant 1 and Tangshan Xu Yang Petrochemical Tangshan Polyethylene Plant 1 are expected to come online in 2023. Exxon Mobil Corporation Huizhou Polyethylene Plant is anticipated to become operational in 2024, while the remaining two projects are expected to start production of polyethylene in 2025.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.